The RNSM announced that it had sold its old factory site for ?8.575 million, which is way above the value shown in the company accounts. It looks as if this will increase the companys Balance Sheet value by approx. 35/40%. The companys Market value (based on the current share price of 42p) is under ?10 million, whilst the Balance Sheet value will be approx. 15/16 million.
This would seem to indicate a seriously undervalued (and cash rich)company.

I have found those at meetings that are normal people, those that pry, those that boast, those that try and convince you to buy shares they hold, whos got the most money, best job, best standing in life. I suppose its OK if your like minded..

I see, maybe it will not be for me, I like genuine people, can not stand glory hunters... Or rampers... I like facts and figures

Me too tonker, if you have never been before then of course you should attend. It may also be a good idea to see what investments others have made. At least you'll have an idea of what topics might be discussed. Nothing worse than having and oil and mining potfolio to find everyone else holds services or manufacturing. Other than that it's always worth checking portfolio sizes to ensure your not wasting your time with big players who make their money on small margin gains.

Other than that you'll have to grin and bear the glory hunters and those who just want to show off their new toys. Havng said this there alot of decent people at events who if you've spoken to previously on the BBs are nice to meet and put a face to the alis.

Wm Ransom FY pretax trebles as it raises dividend, sees sunny year ahead
AFX


LONDON (AFX) - William Ransom & Son PLC said pretax profits trebeled in the year to March 31, with higher sales in all areas of the business and an omtimistic outlook for the current year giving it the confidence to boost its dividend by 7 pct.

Full-year pretax profit before exceptional items rose to 3.4 mln stg from 1.1 mln the year earlier.

Sales climbed to 32.5 mln stg from 19.8. Of these, sales at its fully integrated Optima unit contributed 11.2 mln stg.

The total dividend was raised to 1.6 pence from 1.5.

'Sales were up across all areas of the business, the new manufacturing units began to perform well in the second half and the integration of Optima is producing some real sales and cost benefits,' Chairman and Chief Executive Tim Dye said.

'I expect the high level of momentum which we achieved at the end of last

year to be sustained throughout the current financial year, and early

indications are that this will be the case,' he added.

Ransom(William) & Son PLC
13 June 2006

For Immediate Release 13 June 2006


WILLIAM RANSOM & SON PLC

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 MARCH 2006

SALES GROWTH IN ALL AREAS DELIVERS SUBSTANTIAL PROFITS RISE

William Ransom & Son plc ("Ransom"), one of the UK's leading natural healthcare
companies, today announces its unaudited preliminary results for the year ended
31 March 2006.

Highlights:

Sales increased by 64%, to 32.5 million (2005: 19.8m)

Organic sales growth of 12%, to 21.3 million (2005: 18.9m)

Group profit before tax* up 209%, to 3.4 million (2005: 1.1m)

Earnings* per share up 30%, to 3.43p (2005: 2.64p)

Gross margins improved to 41.5% (2005: 38.8%)

Consumer healthcare sales growing at 15% p.a.

6th and largest acquisition in 4 years - Optima - underlying sales
growth of 10% p.a.

Integration of sales and marketing yielding cross-selling benefits

New manufacturing units performing to plan

Total dividend up 7%, to 1.6p (2005: 1.5p)

* before amortisation and exceptional items


Tim Dye, Chairman and Chief Executive of Ransom, commenting on the preliminary
results and outlook said,

"It's been a very good year. Sales were up across all areas of the business, the
new manufacturing units began to perform well in the second half and the
integration of Optima is producing some real sales and cost benefits. As a
result, profitability has increased greatly, with further upside potential.

The growth of the natural consumer healthcare market, driven by demographics and
social trends, continues to outstrip the standard over-the-counter healthcare
market. I expect the high level of momentum which we achieved at the end of last
year to be sustained throughout the current financial year, and early
indications are that this will be the case."


For further information please contact:

William Ransom & Son plc On the day: 020 7466 5000
Tim Dye - Chairman & Chief Executive Thereafter: 01462 437615
Robert Howard - Finance Director

Buchanan Communications 020 7466 5000
Charles Ryland / James Strong / Simon Potter



Chairman's Statement


The year to 31 March 2006 was a very good one for the Group. Our largest
acquisition to date, of Optima Health and Nutrition, was completed in June 2005
and its integration proceeded quickly and effectively, bringing benefits across
the Group. Both of the newly-constructed manufacturing facilities achieved their
planned levels of productivity by the end of the year and contributed to a very
strong Group performance in the second half and a good performance overall.

Results

Group profit before tax, amortisation and exceptional items rose substantially,
by 209%, to 3.4 million (2005: 1.1m). Group sales rose by 64%, to 32.5
million (2005: 19.8m), of which Optima contributed 11.2 million. Excluding
Optima and discontinued operations, underlying sales rose by 12%, to 21.3
million (2005: 18.9m). Earnings per share (after amortisation and exceptional
items) rose to 1.03p (2005: loss of 0.46p). Before amortisation and exceptional
items, earnings per share rose by 30%, to 3.43p (2005: 2.64p). The Group's net
debt at the end of the year was 6.8 million (2005: 2.6m). Interest cover
(EBITA:net interest) for the period was a comfortable 7.6 times (2005: 4.9
times).

Dividend

The Board proposes to pay a final dividend of 1.10p, bringing the total dividend
to 1.60p, an increase of 7% over last year (2005: 1.50p). Once approved, the
dividend will be payable on 2 October 2006 to all shareholders on the register
on 1 September 2006.

People

I would like to thank staff throughout the Group for their contribution to the
success of Ransom during the year. Particular thanks go to those involved and
affected by the integration of Optima's sales and marketing functions and to
manufacturing staff, who in many cases 'went the extra mile' to get the new
production units operating at target levels.

The appointment to the Board in June 2005 of three new executive directors -
Steve Quinn, Fred Whitcomb and David Wilkie - has introduced additional and
valuable high level sales, marketing, national account and supply chain
management expertise. I would like to thank again William Nabarro, who resigned
in March 2006, for his excellent contribution over two-and-a-half years as a
non-executive director. He has been replaced by Tim Bridge, who brings great
experience of profitably growing a long-established business, organically and
through acquisition.

Outlook

The Group has built itself a strong position in the natural consumer healthcare
market, whose growth, driven by demographics and social trends, continues to
outstrip the standard over-the-counter healthcare market. Based on continued
market growth, integration benefits from Optima and on further recent natural
product contract manufacturing success, I expect the high level of momentum
which we achieved at the end of last year to be sustained throughout the current
financial year, and early indications are that this will be the case.

We continue to look for acquisition opportunities in what is still a fragmented
market, but it is not imperative that we make further purchases. Our
infrastructure is well-matched to our business and we will not be drawn into
over-paying for acquisitions, especially because our in-house new product
development and distribution capability can themselves provide good organic
growth.

Operating and Financial Review

From having no presence at all in consumer healthcare in 2000, Ransom has
established itself as one of the largest independent companies in the UK natural
consumer healthcare market.

At the same time, the Group has fundamentally reorganised and updated its
production capabilities and now has two modern niche manufacturing facilities,
specialising in natural healthcare product formulation and manufacture.

The key operating issues over the course of the year to 31 March 2006 were the
attainment of the targeted levels of productivity at the new manufacturing units
and the integration of the Group's largest acquisition to date, Optima Health
and Nutrition, following its purchase in June 2005. By the end of the year,
after a slow start, the new production facilities were operating to their
planned levels of productivity. Optima's sales and marketing teams were
integrated immediately post-acquisition, with consequent cross-selling benefits
and operational cost savings.

The result was a good financial performance across the Group, with sales rising
by 64%, to 32.5 million (2005: 19.8m), of which Optima contributed 11.2
million. Excluding Optima and discontinued operations, underlying sales rose by
12%, to 21.3 million (2005: 18.9m). Group profit before tax, amortisation and
exceptional items rose substantially, by 209%, to 3.4 million (2005: 1.1m).

Consumer Healthcare

Consumer healthcare sales, which are comprised of branded healthcare products,
grew by 113%, to 24.4 million (2005: 11.5m); in its nine months as part of the
group, Optima accounted for 11.2 million of this growth. Excluding Optima, the
underlying growth rate of consumer healthcare brands was 15%.

Within the good level of consumer healthcare growth, there was a very strong
performance in exports of Radian B, which rose by 73% to 1.9 million (2005:
1.1m) and in UK sales of Metanium, which grew by 25% to 0.9 million (2005:
0.7m). Radian B's UK sales were disappointing, declining to 0.6 million (2005:
0.8m), although early indications are in the current financial year that the
decline may have been reversed in response to new promotional efforts. Health
Perception's sales rose by 7%, to 7.4 million (2005: 6.9m), and produced a
greater improvement in profitability resulting from sales cost savings arising
from the Optima acquisition. Some of the smaller brands, such as Snufflebabe,
saw very high percentage growth rates from a small base.

Optima's performance in its first nine months with the Group was good. On a
like-for-like basis, over the twelve months to 31 March 2006, combined UK and
Eire sales grew by 10% and other export sales grew by 11%.

The Optima, Health Perception and Ransom sales and marketing teams were
integrated directly after Optima joined the Group in June. Some long-term cost
savings were made in the process. We now have sales teams for each of national
accounts (such as multiple pharmacy, multiple healthfood stores and multiple
grocery), independent pharmacy, and independent healthfood stores, giving us
what is probably the most comprehensive distribution of natural healthcare
products in the UK market. The benefit of cross-selling products into the
different channels is already being realised with, for example, brands such as
Optima's Allergenics products now being sold by Ransom's pharmacy sales team.

Exports of consumer healthcare products rose by 176% to 4.7 million (2005:
1.7m), of which 2.1 million arose from Optima products. Excluding Optima,
exports grew by 53%. Export markets and agents for Ransom and Optima consumer
healthcare products, the management of which was also integrated in June, have
also proven to be complementary, giving rise to further cross-selling benefits.
Radian B's success in the Middle East accelerated following the integration. The
Group already has good distribution in the Middle East and in countries such as
USA, France, Italy and Eire and the export distribution network is growing fast.

There is a full new product development pipeline and several new natural
healthcare products were introduced in the course of the year, with many more
planned for the current year. New product development supported by strong
distribution is key to sustaining growth in this market.

The recent implementation of the Traditional Herbal Medicinal Products Directive
(THMPD) in the UK, which allows companies until 2011 to register their herbal
products with appropriate manufacturing and stability data should, we believe,
favour our company, given our special combination of botanical and
pharmaceutical expertise.

Ransom Pharmaceuticals

Ransom Pharmaceuticals manufactures the Group's own MHRA (Medicines and
Healthcare products Regulatory Agency)-licensed products as well as
pharmaceuticals and over-the-counter products for third parties. Sales to third
parties grew by 7% to 4.6 million (2005: 4.3m), and were skewed significantly
towards the second half. The second half bias reflects the new manufacturing
unit reaching its target level of output in the second six months, as well as
underlying growth in the business both through higher volume of existing
contracts and as a result of winning new business. Now that the plant is
operating at its planned level of throughput, we expect that the modern facility
will enable us to win further new contract business.

Ransom Natural Products

Ransom Natural Products ('RNP') principally manufactures botanical extracts for
use in finished products made by Ransom Pharmaceuticals, as well as for sale to
third parties. These extracts are typically used as Active Pharmaceutical
Ingredients ('APIs') by pharmaceutical companies or as nutraceutical ingredients
by food and drink manufacturers. Sales to third parties rose by 16% to 3.6
million (2005: 3.1m, on an equivalent basis).

RNP's sales were also weighted towards the second half, which again reflected
the site reaching its target output in the second six months, although much of
the growth reflects fulfillment of the order backlog which arose during the
move. Now that outstanding customer orders have been satisfied, RNP is seeking
to develop new business and customers, especially in the functional food sector.

RNP's participation in the EU-funded cannabis consortium continued in the year.
The consortium is seeking to develop extracts of cannabis for the treatment of
migraine and rheumatoid arthritis.

Financial

The greatly-improved financial performance in the year reflects the overall
consumer healthcare performance (including 9 months of Optima) and a net
contribution, in the second half only, from the new manufacturing units.

Sales of continuing operations rose by 64%, to 32.5 million (2005: 18.9m).
Underlying sales growth was responsible for 12 percentage points of this rise,
with a contribution of 9 months' sales from Optima comprising the remainder.
Exports accounted for 22% of sales, up from 18% in 2005, due principally to the
good export performance of consumer healthcare brands.

Gross margin improved to 41.5% (2005: 38.8%), and in the absence of the
exceptional cost of sales attributed to slow commissioning of the new
manufacturing plants, would have reached 43.3%.

Operating expenses, excluding the bad debt provision relating to Food Brokers
Ltd, rose by 62%, to 11.6 million (2005: 7.2m). Optima's operating expenses of
3.2 million and goodwill amortisation of 0.7m relating to the acquisition
accounted for 3.9 million of this rise. The balance of 0.5 million was due
principally to increased advertising and promotion. A settlement with the
administrator of Food Brokers Ltd produced a net reimbursement of 80,000
against last year's bad debt provision. We expect to receive a further, smaller
payment as an ordinary creditor in the current year.

Interest costs rose to 0.4 million (2005: 0.1m) due to the increase in the
term and overdraft facilities with Barclays Bank plc, which were used to
part-finance the acquisition and working capital requirements relating to
Optima.

Operating profit before amortisation and exceptional items rose by 209% to 3.8
million (2005: 1.2m), producing an operating margin of 11.9% (2005: 5.9%).

Basic earnings per share rose to 1.03p (2005: loss of 0.46p). Before
amortisation and exceptional items, earnings per share rose by 30% to 3.43p
(2005: 2.64p).

Net cash inflow from operating activities was 2.6 million (2005: 0.2m). Stocks
fell by 0.3 million in the year, with the major reduction being due to seasonal
factors at Optima. Debtors rose by 1.7 million due to the very high sales
levels in the final quarter.

Capital expenditure in the year amounted to 0.7 million as the Group completed
its investments in the new manufacturing facilities. Proceeds of 0.1 million
were received from the sale of fixed assets.

Optima Health and Nutrition was acquired in June 2005 for a total cost of 23.0
million. At the time of the acquisition, Optima had an overdraft of 0.5
million, which was also acquired. The acquisition was funded in part by the
issue of new shares, which raised net proceeds of 19.8 million, and the
increase in bank term facilities of 4.9m, of which 0.8 million was repaid in
the year. Reorganisation costs of 0.1 million were paid in the year.

At the end of the year the group had net debt of 6.8 million (2005: net debt
2.6m) and shareholders' funds of 37.3 million (2005: 17.5m).

RNS Number:6854L
Ransom(William) & Son PLC
07 November 2006


FOR IMMEDIATE RELEASE 7 November 2006



William Ransom & Son plc


Notification of Interim Results



William Ransom & Son plc, one of the UK's leading natural healthcare companies,
will announce its Interim Results for the six months ended 30 September 2006 on
Thursday 16 November 2006.


For further information please contact:


Buchanan Communications

Charles Ryland / James Strong / Ben Romney +44 (0)20 7466 5000






This information is provided by RNS
The company news service from the London Stock Exchange


Lets see if these are going to be as good as expected. Small tick up today.

Another penny rise. Maybe sentiment is changing!!

and i thought this was the company that made the Rolls Royce of lawn mowers

Really cynic lol, its Optima Health & Nutrition that I think will do very well with increased offerings in the high street shops like Holland & Barrett, Boots, GNC, superdrug and the superstores Tesco and Waitrose. Look for the label when your doing your Christmas shop and you may well be surprised!!

I hold a GNC gold card and these products seam to be on the increase, well get more shelf space which in my eyes tells me that they must be selling. Lecithin seams to be popular and I expect more so after xmas with people wanting to shed the extra pounds with a product that contains no chemicals etc.

This company is under valued IMO, a conservative estimate 70p+. Yes I am a share holder.

I agree with that estimate Goal, 75ish was my estimate, nice to see I'm not the only person on money am holding!

Cynic, what do you mean? I thought this company was involved in the health food/ supplements market.. Or am I missing one of your bad jokes lol

explosive, I own a health shop, and the trade i do with optima health is massive... As you said Lecithin granuals sell but the biggest seller is Organic Choice 3,6,9 and Pommegranate juice.....

One day people will wake up & see what a bargain William Ransom & Sons really is @ around 50p.

Tonker was mearly going on what I see when I visit my local GNC, very pleased to know though that you do trade with Optima and also other Optima products sell well.

Ransom(William) & Son PLC
16 November 2006




For Immediate Release 16 November 2006



WILLIAM RANSOM & SON PLC


INTERIM RESULTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2006



IMPROVED LEVELS OF PROFITABILITY

ACROSS THE GROUP


William Ransom & Son plc ('Ransom'), one of the UK's leading natural healthcare
companies, today announces its unaudited interim results for the six months
ended 30 September 2006.


Financial Highlights:


Group sales increased by 32% to 17.7m (2005: 13.4m)
Profit before tax and amortisation of goodwill up over 170% to 1.9m
(2005: 0.7m)
EPS excluding amortisation of goodwill and exceptional items increased by
12%, to 1.63p (2005: 1.46p)

Gross margins improved from 40.2% to 42.5%


Operational Highlights:


Improved levels of profitability in all areas of the business
Development of several exciting new products due for launch in the second
half of the year
New export markets with local distribution partners and new Italian
subsidiary established
Move to a new centralised 52,000 square foot distribution centre in
Bradford completed


Tim Dye, Chairman and Chief Executive of Ransom, commenting on the interim
results and outlook, said,


'It is encouraging to see further improved levels of profitability in all areas
of the business. The key objectives that we set ourselves for the first half of
the year have been met and the Group continues to trade in line with our
expectations. Our normal second half bias should be further enhanced by the
effect of new product introductions, export business development and anticipated
additional operational efficiencies.


With the key elements of the acquired businesses now integrated, and
manufacturing performing to target, we are again able to consider expansion
opportunities in both the UK and overseas. The Board believes that the short and
medium term outlook for the Group is good.'


For further information please contact:

William Ransom & Son plc On the day: +44 (0)20 7466 5000
Tim Dye - Chairman & Chief Executive Thereafter: +44 (0)1462 437615
Robert Howard - Finance Director

Buchanan Communications +44 (0)20 7466 5000
Charles Ryland / James Strong / Ben Romney




Chairman's Statement



Results



In the six months to 30 September 2006, group profit before tax and amortisation
of goodwill rose significantly, to 1.9m (2005: 0.7m). Operating profit
increased to 1.3m (2005: 0.3m). Basic earnings per share rose to 0.63p (2005:
loss of 0.15p) and excluding amortisation of goodwill and exceptional items,
earnings increased by 12% to 1.63p (2005: 1.46p). Group sales increased to
17.7m (2005: 13.4m). The Board declared an unchanged dividend of 0.50p per
share, payable on 10 January 2007 to all shareholders on the register on 15
December 2006.


Operating Review


It has been very pleasing to see further improved levels of profitability in all
areas of the business alongside the attainment of key operational objectives in
the first half of the year.


We have worked hard to maintain a high level of new product innovation and have
developed several exciting new products due for launch in the second half, as
well as having introduced earlier this year an extensive range of new products
for export markets. We expect the new product launches to benefit from the
cross-selling opportunities which the enlarged Group provides.


Our innovative and dynamic range of natural consumer healthcare products has
enabled us to establish new export markets with local distribution partners. The
selection of suitable partners and adaptation of packaging to suit local
requirements is time-consuming and can be costly, but it will yield benefit in
the second half and beyond. Additionally, at the beginning of the year, in
Italy, which is a highly developed market for natural healthcare products such
as ours, we invested in the establishment of our own marketing office, with a
range of 60 products specifically selected and packaged for the Italian market.
After a slightly slow start, the business is now growing well. Branded consumer
healthcare exports to the Middle East have not yet reached the exceptionally
high sales rates of last year, but some pick-up is expected in the second half,
driven in part by new product range extensions.


Growth in the UK glucosamine market, which until recently had been very high
through all channels, has become more patchy, although it is still a very
attractive market overall. In part the change is due to a degree of uncertainty
caused by a potentially shifting regulatory environment for glucosamine, which
we are monitoring carefully. Under our Health Perception and Optima brands, we
have responded to the changing market with an adapted and expanded product range
which seems, initially at least, to be showing very positive effects.


Margins in consumer healthcare have seen further benefit in the first half from
the integration of more processes of the acquired businesses. The move earlier
this month to the Group's new 52,000 square foot centralised distribution centre
in Bradford took considerable planning and will realise additional gains from
the fourth quarter forwards.


Manufacturing volumes and efficiency have improved steadily in the year to date,
as we have continued to optimise production processes against a background of a
growth in new contract manufacturing business.


Financial Review


Gross margins again improved, from 40.2% to 42.5%, which reflected a greater
emphasis on branded consumer healthcare products following the acquisition of
Optima, as well as a general improvement in gross margin in all activities
across the Group. Expenses rose by 1.2m as a result of the effect of
consolidating Optima for the full six months, compared with three months for the
comparable period. Underlying expenses fell slightly. Operating margin improved
to 7.3% (2005: 2.6%).


There was a net cash inflow from operating activities of 2.0m (2005: outflow of
0.4m). Stocks rose by 0.4m principally within the manufacturing divisions as
core stock levels were rebuilt following the very high sales at the end of the
last financial year. Debtors rose by less than 0.1m, while creditors fell by
0.3m.


Capital expenditure of 0.3m was within the depreciation figure of 0.5m.
Overall net debt was reduced by 0.9m to 5.8m after the repayment of 0.5m of
the senior term loan.



Outlook


The Group continues to trade in line with our expectations and the Board
believes that its short and medium term outlook is good. The beneficial impact
in the second half of the seasonal bias of our business should be further
enhanced by the effect of new product introductions, export business development
and anticipated operational efficiencies. In the slightly longer term, the
shifting UK regulatory situation regarding glucosamine presents opportunities
and threats to which we shall remain alert.


The natural healthcare market fundamentals remain very attractive and are, we
believe, conducive to sustained long-term growth in the sector. With the key
elements of the acquired businesses now integrated, and manufacturing performing
to target, we have begun again to consider opportunities for expansion in the UK
and overseas by acquisition in what are still fragmented markets. Growth in the
natural healthcare markets has attracted some high M&A multiples, but we remain
cautious in our approach and will not be drawn into over-paying. As I have
mentioned in previous announcements, we are also actively seeking another
suitably-qualified independent non-executive director to strengthen further our
Board for what promises to be an exciting period of further expansion.



Tim Dye

Chairman and Chief Executive





Consolidated Profit and Loss Account

For the six months ended For the year
30 September ended 31
March
2006 2005 2006
'000 '000 '000
Restated Restated

Turnover 17,744 13,426 32,510

Cost of sales (10,201) (7,416) (18,417)
Exceptional cost of sales - (607) (607)

Total cost of sales (10,201) (8,023) (19,024)



Gross profit 7,543 5,403 13,486

Selling and distribution costs (3,598) (2,802) (6,632))

Administrative expenses (2,641) (2,256) (4,994)
Provision for bad debt - - 80

Group operating profit 1,304 345 1,940

Net interest payable (211) (177) (439)


Profit before taxation 1,093 168 1,501

Tax on profit / (loss) on ordinary
activities (561) (261) (780)

Profit / (loss) after taxation 532 (93) 721

Equity minority interests 3 - 2

Profit / (loss) attributable to
shareholders 535 (93) 723





Earnings per share:
Basic earnings / (loss) per share 0.63p (0.15p) 1.00p
Diluted earnings / (loss) per share 0.63p (0.15p) 1.00p


Statement of total
recognised gains and
losses

Reported profit / (loss) 535 (93) 723
attributable to
shareholders

Exchange adjustments (7) - 2
offset in reserves


Total recognised gains / 528 (93) 725
(losses) for the period

Prior year adjustment (60) - -


Total gains and losses
recognised since the 468 (93) 725
last annual
report




Balance Sheet



At 30 September At 31 March
2006 2005 2006
'000 '000 '000
Restated Restated
Fixed assets
Intangible assets 28,701 30,387 29,548
Tangible assets 5,998 6,487 6,263

34,699 36,874 35,811

Current assets
Stocks 7,334 7,623 6,970
Debtors 7,664 6,907 7,616
Cash at bank and in hand 920 105 2,220

15,918 14,635 16,806

Creditors: Amounts falling due within one (8,440) (9,230) (9,521)
year

Net current assets 7,478 5,405 7,285

Total assets less current liabilities 42,177 42,279 43,096

Creditors: Amounts falling due after more
than (4,745) (5,671) (5,283)
one year
Provision for liabilities and charges (668) (281) (659)

Net assets 36,764 36,327 37,154

Capital and reserves
Called up share capital 8,433 8,433 8,433
Share premium account 21,978 21,979 21,978
Profit and loss account 6,358 5,915 6,745

Total equity shareholders' funds 36,769 36,327 37,156

Equity minority interests (5) - (2)


Capital employed 36,764 36,327 37,154




Cash Flow Statement

For the six months ended For the year
30 September ended 31 March
2006 2005 2005
'000 '000 '000
Restated Restated

Net cash inflow / (outflow) from
operating activities 2,005 (418) 2,609

Returns on investment and servicing of
finance
Interest received 1 - 13
Interest paid (208) (177) (415)
Interest element of finance lease
rental payments (4) - (10)

(211) (177) (412)

Taxation received
UK corporation tax paid (78) (247) (745)

Capital expenditure and financial
investment
Payments to acquire tangible fixed
assets (278) (112) (662)
Receipts from sale of tangible fixed
assets 9 - 78
Receipts from sale of intangible
fixed assets - - 5

(269) (112) (579)

Acquisitions and disposals
Purchase of subsidiary undertaking - (23,077) (12,569)
Overdraft balances acquired - (521) (524)

- (23,598) (13,093)

Equity dividends paid - - (1,265)

Cashflow before use of liquid
resources 1,447 (24,552) (13,485)

Financing
Proceeds from new bank loans - 4,900 4,900
Issue of ordinary share capital - 20,390 10,000
Issue expenses for shares - (568) (569)
Repayment of bank loans (500) (250) (750)
Capital element of finance lease
rental payments 26 - 24

(474) 24,472 13,605

Increase / (decrease) in cash 973 (80) 120





Notes on the financial statements for the six months ended 30 September 2006


1. The results for the six months ended 30 September 2006 and
30 September 2005 are unaudited. They have been prepared on the basis of
accounting policies expected to be adopted for the year ended 31 March 2007. The
figures for the year ended 31 March 2006 have been extracted from the full
accounts for that year which have been delivered to the Registrar of Companies
and on which the auditors have given an unqualified report.
During the year the Group adopted FRS 20 'Share - based Payment'. The adoption
of this standard constitutes a change in accounting policy therefore the impact
has been reflected as a prior year adjustment in accordance with FRS 3
'Reporting financial performance'.


The standard requires that where shares or rights to shares are granted to third
parties,including employees, a charge should be recognised in the profit and
loss account based on the fair value of the shares at the date the grant of shares
or right to shares is made.


The effect of the adoption of FRS 20 on prior year comparatives is to reduce the
profit attributable to shareholders by 13,000 in the six months to 30 September
2005 and by 25,000 in the year to 31 March 2006.


2. Earnings per share

Basic earnings per share are based on the profit on ordinary activities after
taxation and on 84,335,207 shares(2005 : 60,692,397 shares), the weighted
average number of shares in issue during the period. The diluted earnings per
share are the same as the basic earnings per share.

For the six months For the year
ended 30 September ended 31 March
2006 2005 2006

Basic earnings / (loss) per share 0.63p (0.15p) 1.00p
Diluted earnings / (loss) per share 0.63p (0.15p) 1.00p
Basic earnings per share excluding
exceptional items 0.63p 0.55p 1.51p
Diluted earnings per share excluding
exceptional items 0.63p 0.55p 1.51p
Basic earnings per share excluding
exceptional items and amortisation 1.63p 1.46p 3.41p
Diluted earnings per share excluding
exceptional items and amortisation 1.63p 1.46p 3.41p


Profit per share excluding all exceptional items, which are disclosed to reflect
the underlying performance of the Company, is calculated on a profit of 535,000
(2005: 332,000).


Profit per share excluding all exceptional items and amortisation, which are
disclosed to reflect the effect of amortisation charges on the performance of
the Company, is calculated on a profit of 1,376,000 (2005: 884,000)


3. Reserves
Share Profit
premium and loss
account account
'000 '000

At 1 April 2006 21,978 6,745
Retained profit - 535
Share option scheme issues 13
Unrealised exchange difference - (7)
Dividends - (928)


At 30 September 2006 21,978 6,358



4. Reconciliation of operating profit with net cash inflow /
(outflow) from operating activities:

For the six months For the year
ended 30 September ended 31 March
2006 2005 2006
'000 '000 '000

Operating profit 1,304 345 1,940
Depreciation 538 265 1,030
Amortisation and impairment of
intangibles 841 552 1,378
Share based remuneration 13 13 25
(Profit) / loss on sale of tangible
fixed assets (4) - 14
(Increase) / decrease in stocks (364) (346) 307
Increase in debtors (48) (915) (1,669)
Decrease in creditors (275) (332) (330)
Cashflows relating to fundamental
reorganisation - - (86)

2,005 (418) 2,609




5. Reconciliation of net cash flow to movement in net debt:

For the six months For the year
ended 30 September ended 31
March
2006 2005 2006
'000 '000 '000

Increase / (decrease) in cash 973 (80) 120
New finance leases and higher
purchase contracts (28) - (80)
Amortisation of loan cost (9) - (28)
Cash inflow from increase in net
debt - (4,615) (4,174)

Change in net debt resulting from
cash flows 936 (4,695) (4,162)
Opening net (debt) / funds (6,771) (2,609) (2,609)

Closing net (debt) / funds (5.835) (7,304) (6,771)


Represented by:

Cash at bank and in hand 920 105 2,220
Bank overdraft (919) (755) (2,670)

1 (650) (450)
Bank and other loans (5,671) (6,654) (6,162)
Finance leases (163) - (159)

Closing net debt (5.835) (7,304) (6,771)





6. Copies of this interim report are being sent to
shareholders. Further copies can be obtained from the Company's registered
office at Alexander House, 40a Wilbury Way, Hitchin, Hertfordshire, SG4 0AP.



This information is provided by RNS
The company news service from the London Stock Exchange

Well I'm happy with that.

Nice move today.

Interim dividend was paid today

:-)

Ransom(William) & Son PLC
16 January 2007


Acquisition of shares for the William Ransom & Son plc Share Incentive Plan


William Ransom & Son (the 'Company') announces that WR Trustees Company Limited,
a wholly owned subsidiary of the Company, has today acquired a total of 172
shares in the Company on behalf of the William Ransom & Son plc Share Incentive
Plan (the 'Plan') at an average price of 54.0p per share. The Plan is an
employee share scheme open to all employees and directors of the Company. The
Company requires that any dividends payable in respect of shares held within the
Plan be used to buy more shares and for the shares to be purchased, by the
Trustee, within 30 days of the dividend being paid. Following that acquisition
of shares, Robert Howard, Finance Director of the Company is now the beneficial
owner of an additional 34 ordinary shares bringing his total beneficial
ownership to 83,290 shares representing 0.1 % of the Company's issued share
capital and Timothy Dye, Chairman of the Company is now the beneficial owner of
an additional 8 ordinary shares bringing his total beneficial ownership to
975,388 shares representing 1.16 % of the Company's issued share capital.




This information is provided by RNS
The company news service from the London Stock Exchange